On this page
fluocinolone acetonide
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 012787-002 | SYNALAR | CREAM | FLUOCINOLONE ACETONIDE | Prescription | AT | RLD RS | |
| 012787-004 | SYNALAR | CREAM | FLUOCINOLONE ACETONIDE | Prescription | AT | RLD RS | |
| 012787-005 | SYNALAR | CREAM | FLUOCINOLONE ACETONIDE | Prescription | AT | RLD RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 71 | Manufacturing (CMC) | Approved | March 28, 2013 | Priority |
| Supplement | 66 | Manufacturing (CMC) | Approved | September 26, 2000 | Priority |
| Supplement | 65 | Manufacturing (CMC) | Approved | July 22, 1996 | Priority |
| Supplement | 61 | Labeling | Approved | March 6, 1995 | — |
| Supplement | 60 | Labeling | Approved | March 6, 1995 | — |
| Supplement | 64 | Labeling | Approved | March 1, 1995 | Standard |
| Supplement | 63 | Manufacturing (CMC) | Approved | November 13, 1992 | Priority |
| Supplement | 62 | Manufacturing (CMC) | Approved | April 24, 1992 | Priority |
| Supplement | 59 | Manufacturing (CMC) | Approved | February 13, 1990 | Priority |
| Supplement | 56 | Manufacturing (CMC) | Approved | April 12, 1989 | Priority |
| Supplement | 58 | Manufacturing (CMC) | Approved | April 4, 1989 | Priority |
| Supplement | 57 | Manufacturing (CMC) | Approved | February 10, 1989 | Priority |
| Supplement | 55 | Manufacturing (CMC) | Approved | December 20, 1984 | Priority |
| Supplement | 54 | Manufacturing (CMC) | Approved | August 29, 1984 | Priority |
| Supplement | 53 | Manufacturing (CMC) | Approved | September 7, 1983 | Priority |
| Supplement | 52 | Labeling | Approved | April 8, 1983 | — |
| Supplement | 50 | Manufacturing (CMC) | Approved | November 19, 1982 | Priority |
| Supplement | 49 | Manufacturing (CMC) | Approved | November 20, 1981 | Priority |
| Supplement | 48 | Manufacturing (CMC) | Approved | November 12, 1981 | Priority |
| Supplement | 43 | Manufacturing (CMC) | Approved | June 26, 1981 | Priority |
| Supplement | 47 | Manufacturing (CMC) | Approved | January 19, 1981 | Priority |
| Supplement | 46 | Manufacturing (CMC) | Approved | January 19, 1981 | Priority |
| Supplement | 45 | Manufacturing (CMC) | Approved | January 19, 1981 | Priority |
| Supplement | 44 | Manufacturing (CMC) | Approved | January 19, 1981 | Priority |
| Supplement | 42 | Manufacturing (CMC) | Approved | July 30, 1980 | Priority |
| Supplement | 40 | Labeling | Approved | February 19, 1980 | — |
| Supplement | 39 | Labeling | Approved | February 19, 1980 | — |
| Supplement | 38 | Manufacturing (CMC) | Approved | October 23, 1979 | Priority |
| Supplement | 37 | Manufacturing (CMC) | Approved | August 13, 1979 | Priority |
| Supplement | 36 | Manufacturing (CMC) | Approved | July 25, 1979 | Priority |
| Supplement | 34 | Manufacturing (CMC) | Approved | April 13, 1979 | Priority |
| Supplement | 31 | Labeling | Approved | January 10, 1979 | — |
| Supplement | 33 | Manufacturing (CMC) | Approved | November 28, 1978 | Priority |
| Supplement | 32 | Labeling | Approved | September 12, 1978 | — |
| Supplement | 30 | Manufacturing (CMC) | Approved | June 4, 1977 | Priority |
| Supplement | 29 | Labeling | Approved | January 4, 1977 | — |
| Supplement | 28 | Labeling | Approved | July 8, 1976 | — |
| Supplement | 27 | Labeling | Approved | December 12, 1975 | — |
| Supplement | 26 | Labeling | Approved | June 26, 1975 | — |
| Original application | 1 | Type 1 - New Molecular Entity | Approved | February 15, 1963 | Priority |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20231122). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Fluocinolone Acetonide Cream, USP is indicated for the relief of the inflammatory and pruritic manifestations of corticosteriod-responsive dermatoses.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Fluocinolone Acetonide Cream, USP is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion. Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. Some plastic films may be flammable and due care should be exercised in their use. Similarly, caution should be employed when such films are used on children or left in their proximity, to avoid the possibility of accidental suffocation. If an infection develops, the use of the occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning, Itching, Irritation, Dryness, Folliculitis, Hypertrichosis, Acneiform eruptions, Hypopigmentation, Perioral dermatitis, Allergic contact dermatitis, Maceration of the skin, Secondary infection, Skin atrophy, Striae and Miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Description
openFDA Drug LabelingDESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents. Fluocinolone Acetonide is included in this class of synthetic corticosteroids. Chemically Fluocinolone Acetonide is Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6α, 11β, 6α)-), with the molecular formula C 24 H 30 F 2 0 6 , a molecular weight of 452.49 and the following structural formula: Each gram of Fluocinolone Acetonide Cream, USP 0.01% contains 0.1 mg fluocinolone acetonide USP in a water washable cream base consisting of mineral oil (and) lanolin alcohols, isopropyl palmitate NF, propylene glycol stearate, cetyl alcohol NF, sorbitan monostearate NF, polysorbate 60 NF, sorbic acid NF, polyoxyl (40) stearate NF, purified water USP, propylene glycol USP with propylparaben NF and methylparaben NF as preservatives. Each gram of Fluocinolone Acetonide Ointment, USP 0.025% contains 0.25 mg of fluocinolone acetonide USP in an ointment base consisting of light mineral oil NF and white petrolatum USP. Chemical Structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Fluocinolone Acetonide Cream, USP 0.01% is supplied in: 15 g tubes NDC 0713-0223-15, and 60 g tubes NDC 0713-0223-60 Fluocinolone Acetonide Ointment, USP 0.025% USP is supplied in: 15 g tubes NDC 0713-0224-15, and 60 g tubes NDC 0713-0224-60 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Distributed by: Cosette Pharmaceuticals, Inc. South Plainfield, NJ 07080 VC7669 Rev. 09/2022 8-FLUOCPLNC3
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: FLUOCINOLONE ACETONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Recalls
Source: FDA Enforcement| Classification | Reported | Firm | Reason | Status |
|---|---|---|---|---|
| Class III | January 8, 2014 | G & W Laboratories Inc | Failed Content Uniformity Specifications; at the 18 month time point. | Terminated |
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 62559-288-15 | 62559-288 | ANI Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (62559-288-15) / 15 g in 1 TUBE | May 8, 2024 |
| 62559-288-60 | 62559-288 | ANI Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (62559-288-60) / 60 g in 1 TUBE | May 8, 2024 |
| 62559-289-15 | 62559-289 | ANI Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (62559-289-15) / 15 g in 1 TUBE | May 8, 2024 |
| 62559-289-60 | 62559-289 | ANI Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (62559-289-60) / 60 g in 1 TUBE | May 8, 2024 |
| 0713-0223-15 | 0713-0223 | Cosette Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (0713-0223-15) / 15 g in 1 TUBE | July 26, 1988 |
| 0713-0223-60 | 0713-0223 | Cosette Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (0713-0223-60) / 60 g in 1 TUBE | July 26, 1988 |
| 0713-0709-15 | 0713-0709 | Cosette Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (0713-0709-15) / 15 g in 1 TUBE | November 5, 2018 |
| 0713-0709-60 | 0713-0709 | Cosette Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (0713-0709-60) / 60 g in 1 TUBE | November 5, 2018 |
| 62559-288 | 62559-288 | ANI Pharmaceuticals, Inc. | — | May 8, 2024 |
| 62559-289 | 62559-289 | ANI Pharmaceuticals, Inc. | — | May 8, 2024 |
| 0713-0223 | 0713-0223 | Cosette Pharmaceuticals, Inc. | — | July 26, 1988 |
| 0713-0709 | 0713-0709 | Cosette Pharmaceuticals, Inc. | — | November 5, 2018 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
| Enforcement | FDA | Recall records |
Generated September 25, 2026 · 13 sections on this page.